Abstract
Aim:
To investigate the anti-lymphoproliferative effect of the prepared recombinant chimeric human/murine anti-cluster of differentiation(CD) 71 monoclonal antibody (AbCD71), which is composed of mouse-derived, antigen-binding variable regions and human-derived constant regions.
Methods:
After plasmids construction and transfection, the expression of AbCD71 in the transfectoma supernatant was determined by the sandwich ELISA. Indirect immunofluorescence assay was used to measure the antigen-binding characteristic and the percent CD71-expressed peripheral blood mononuclear cells (PBMC). The antibodies were purified from the ascites via diethylaminoethyl(DEAE)-Sephadex A-50 chromatography and then identified by SDS-PAGE. At last, inhibitory effect of AbCD71 on PHA-induced PBMC proliferation was calculated by methyl thiazolyl tetrazolium (MTT) assay.
Results:
Constant domain of heavy chain(CH) and light chain(CL)of AbCD71 were in the human Cγ family and human Cκ family, respectively. AbCD71 could compete with its original murine mAb to bind with CD71-positive human leukemia cell line CEM cells. AbCD71 could inhibit the peripheral blood mono-nuclear cell proliferation induced by phytohemagglutinin(PHA) in vitro in a dose-dependent manner, especially at time-points 0 and 12 h after induction. There was no statistical difference when compared with original murine mAb.
Conclusion:
The AbCD71 is a promising immunosuppressant. Our approach to blocking CD71 with the chimeric human/murine mAb provides a novel strategy for prolonging allograft survival.
Similar content being viewed by others
Article PDF
References
Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML . The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121: 144–58.
White S, Taetle R, Seligman PA, Rutherford M, Trowbridge IS . Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res 1990; 50: 6295–301.
Kreitman RJ, Pastan I . Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 1997; 90: 252–9.
Mirick GR, Bradt BM, Denardo SJ, Denardo GL . A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004; 48: 251–7.
Presta LG . Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58: 640–56.
Klee GG . Human anti-mouse antibodies. Arch Pathol Lab Med 2000; 124: 921–3.
Gonzales NR, De Pascalis R, Schlom J, Kashmiri SV . Minimizing the immunogenicity of antibodies for clinical application. Tumour Biol 2005; 26: 31–43.
Hwang WY, Foote J . Immunogenicity of engineered antibodies. Methods 2005; 36: 3–10.
Woodward JE, Bayer AL, Chavin KD, Boleza KA, Baliga P . Antitransferrin receptor monoclonal antibody: a novel immunosuppressant. Transplantation 1998; 65: 6–9.
Jason J, Archibald LK, Nwanyanwu OC, Bell M, Jensen RJ, Gunter E, et al. The effects of iron deficiency on lymphocyte cytokine production and activation: preservation of hepatic iron but not at all cost. Clin Exp Immunol 2001; 126: 466–73.
Lio D, Candore G, Cigna D, D'Anna C, Di Lorenzo G, Giordano C, et al. In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression. Mech Ageing Dev 1996; 89: 51–8.
Daniels TR, Delgado T, Helguera G, Penichet ML . The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006; 121: 159–76.
Keyna U, Nusslein I, Rohwer P, Kalden JR, Manger B . The role of the transferrin receptor for the activation of human lymphocytes. Cell Immunol 1991; 132: 411–22.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Project supported by grants from the Hi-Tech Research and Development Program of China (No 2006AA02Z158) and Hubei Key Sci & Tech R&D Programme (No 2006AA301A05).
Rights and permissions
About this article
Cite this article
Lei, P., He, Y., Ye, Q. et al. Antigen-binding characteristics of AbCD71 and its inhibitory effect on PHA-induced lymphoproliferation. Acta Pharmacol Sin 28, 1659–1664 (2007). https://doi.org/10.1111/j.1745-7254.2007.00623.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00623.x
Keywords
This article is cited by
-
Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells
Cancer Immunology, Immunotherapy (2013)
-
Preparation and identification of scFv and bsFv against transferrin receptor
Journal of Huazhong University of Science and Technology [Medical Sciences] (2008)